Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0011854 (
type 1 diabetes
)
20,749
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
It is rather difficult to draw conclusions from reported C-peptide values, as the methods for determination differ, and C-peptide may be measured in serum or in urine with the patient fasting or after stimulation. We have followed prospectively 49 children with
IDDM
with regular determinations of serum C-peptide fasting and after a standardized breakfast. A subgroup of seven patients have been studied more thoroughly with 24-hour-profile of serum C-peptide, C-peptide excretion in urine, and stimulation by i.v. glucose + i.v.
arginine
. Our results indicate that the stimulation of the beta cells usually reaches a maximum around a blood glucose level of 10-12 mmol/l leading to a curve linear relationship between serum C-peptide and blood glucose. Thus a simple quotient is not so useful but the degree of stimulation should be stated and actual blood glucose value noticed. Stimulation with a standardized breakfast gives roughly the same information as maximal stimulation with i.v. glucose +
arginine
, and little extra information is found by a 24-hour-profile. Urinary C-peptide may give valuable information if it is related to the actual degree of metabolic balance. It can be of special interest in patients with very low serum C-peptide levels.
...
PMID:Methodological aspects on C-peptide measurements. 657 23
In the present study we have investigated the effect of IgG isolated from sera of newly diagnosed insulin-dependent diabetic patients (
IDD
-IgG) on insulin release of column-perifused isolated mice islets of Langerhans in the presence and absence of guinea pig complement. The insulin release is highly significantly (p less than 0.01) increased by
IDD
-IgG as compared with normal serum IgG in the presence of untreated as well as heat-inactivated GPNS. However, complement exposure suppressed insulin release significantly (p less than 0.01) in each period of perifusion. After perifusion in the presence of complement the
arginine
-stimulated insulin secretion was 6 times lower than without complement exposure of perifused islets before.
...
PMID:Insulin release from mouse islets perifused with serum IgG from newly insulin-dependent diabetics. 676 54
The spontaneously diabetic BB Wistar rat shows many characteristics analogous to human insulin-dependent diabetes (
IDDM
). These include inappropriately normal immunoreactive glucagon in the presence of hyperglycemia, absolute hyperglucagonemia with severe ketosis, and hyperresponsiveness to exogenous
arginine
in vivo. We used an in situ pancreas preparation to further study portal vein glucagon responses to intravenous
arginine
. In normal rats, magnitude of response was correlated with prestimulation levels. Basal levels were significantly increased in hyperglycemic diabetics compared to controls, but responses to
arginine
were attenuated in both absolute and relative terms. Comparisons of responses with poor and good prior diabetes control showed no significant differences. Thus, a further anomaly of glucagon secretion has been identified in these rats.
...
PMID:Arginine-induced glucagon secretion in the spontaneously diabetic BB Wistar rat. 684 59
To elucidate the precise significance of pancreatic A-cell hypersecretion in the pathogenesis of diabetes mellitus, the change in the immunoreactive glucagon (IRG) response to intravenous
arginine
was studied in both nonobese, hypoinsulinemic non-insulin-dependent (NIDDM) and insulin-dependent diabetic (
IDDM
) subjects whose blood glucose responses and plasma immunoreactive insulin (IRI) simulated those of healthy subjects with the aid of the artificial beta-cell system that we originally developed. In both five NIDDM and five
IDDM
subjects, blood glucose responses and plasma IRI after
arginine
challenges were made equivalent to those seen in healthy subjects by infusing insulin in response to blood glucose, revealing that previously exaggerated IRG responses were made completely similar to the responses in healthy subjects. In summary, these results clearly demonstrate that the exaggerated response of A-cell secretion against
arginine
challenges in insulin-deficient diabetics is secondary to insulin lack, and the perfect normalization of its response is achieved only when both plasma insulin concentration and glycemic control simulate those of healthy subjects.
...
PMID:Perfect normalization of excessive glucagon responses to intravenous arginine in human diabetes mellitus with the artificial beta-cell. 700 90
To explore humoral immunity in insulin-dependent diabetic (
IDDM
) patients, we studied insulin release from isolated mouse islets stimulated by glucose + theophylline after incubation with the sera of these patients and complement. Eleven of 21
IDDM
sera suppressed the stimulated insulin release while the
arginine
-stimulated glucagon release remained unchanged. Morphologic evidence and the trypan-blue exclusion test suggested that the suppression of insulin release was due to a cytotoxic effect of the sera. No beta-cell inhibition of morphologic damage was detectable in the presence of sera from 30 healthy subjects, 8 non-insulin-dependent diabetic patients, and 5 nondiabetic patients with autoimmune diseases. Beta-cell inhibition by
IDDM
sera was not observed when complement was omitted. After serum fractionation, the cytotoxic potency of
IDDM
sera was located in the immunoglobulin G fraction. Using human islets, insulin release was suppressed by 3 of 6
IDDM
sera. Complement-dependent cytotoxicity was found in 1 of 5 recent-onset
IDDM
patients and 11 of 16
IDDM
patients with autoimmune phenomena. It was associated in all cases with the presence of islet cell antibodies as detected by immunofluorescence, and with the presence of circulating lymphocytes which suppressed insulin release in vitro. Complement-fixing antibodies may contribute to the selective beta-cell damage in
IDDM
.
...
PMID:Complement-fixing Islet cell antibodies from some diabetic patients alter insulin release in vitro. 703 Aug 31
Arginine
metabolism via nitric oxide (NO) synthase and other pathways was studied in coronary endothelial cells (EC) from the spontaneously diabetic BB rat, an animal model of human
type I diabetes mellitus
(
IDDM
). EC were prepared from insulin-treated diabetic BB (BBd) and non-diabetes-prone BB (BBn) rats. Basal NO synthesis was studied in EC cultured for 48 h in medium containing 0.4 mM L-
arginine
. At the end of the culture period, the medium was analyzed for nitrite and nitrate (two major end stable oxidation products of NO), and the cells were used to determine
arginine
uptake and metabolism and the activities of some
arginine
-degrading enzymes. For studies of
arginine
metabolism, cells were incubated at 37 degrees C for 1 h in Krebs-Henseleit bicarbonate buffer (pH 7.4) containing 1 mM L(-)[1-14C]
arginine
or L(-)[1-14C]ornithine. The rates of production of nitrite plus nitrate by BBd EC were only 15% of those of BBn cells. This impaired NO synthesis in BBd EC was not due to alterations in
arginine
uptake, NO synthase activity, or intracellular
arginine
concentrations but might have resulted from a limited intracellular availability of cofactors of NO synthase. In addition to the
arginine
-NO pathway,
arginine
was found to be metabolized to urea, ornithine, and, to a much lesser extent, CO2 via arginase and ornithine aminotransferase. The activities of arginase and the formation of ornithine and urea from
arginine
were decreased by 90% in BBd compared with BBn cells. These results, coupled with the reduced NO synthesis, indicate metabolic defects in
arginine
metabolism in BBd EC.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:Impaired arginine metabolism and NO synthesis in coronary endothelial cells of the spontaneously diabetic BB rat. 748 63
IDDM
is known to be associated with genes of HLA complex, particularly alleles of HLA-DQ. The 40-kb TAP gene complex is located approximately 150 kb centrometric to the DQB1 locus. The TAP1-TAP2 protein heterodimer is required for normal expression levels of class I, molecules on the surface of cells. While present evidence implicates HLA-DQ as the major susceptibility locus in
IDDM
, as class I expression apparently plays a role in the progression of disease, the possibility exists that the association attributed to HLA-DQ is in fact due to an association with the TAP genes. Several studies have concluded that the alleles of TAP1 are not significantly associated with
IDDM
; this report concentrates on the more telomeric TAP2 locus. During this investigation, six previously described TAP2 alleles were identified in 208 normal Caucasians and 241 Caucasian diabetics. Sequence analysis of cDNA clones identified a seventh allele of TAP2, TAP2*F, which contains an
arginine
-to-cystine interchange at amino acid position 651. Overall, our results indicate only a modest association of
IDDM
with TAP2; however, the newly described TAP2*F allele was found to be significantly increased in a modest subset of our large diabetic population. These data, generated from the same population of controls and diabetics we previously studied at all other relevant MHC loci, provide additional evidence that the HLA susceptibility to
IDDM
maps to HLA-DQ.
...
PMID:TAP2 association with insulin-dependent diabetes mellitus is secondary to HLA-DQB1. 755 30
Because particular human leukocyte antigen (HLA) DQ alleles are the major predisposing factors for
type 1 diabetes
mellitus (
IDDM
), we investigated whether they are shared by other endocrine autoimmune diseases. We, therefore, analyzed the HLA DQ genotypes of 171 patients with
IDDM
, 271 with Graves' disease (GD), 65 with Hashimoto's thyroiditis, 51 with postpartum thyroiditis, 53 with Addison's disease (AD), and 271 healthy controls. HLA DQA1 and DQB1 alleles were defined by polymerase chain reaction and sequence-specific oligonucleotide hybridization as well as by single strand conformational polymorphism analysis. HLA DQA1*0501 was significantly more frequent in
IDDM
(60%), GD (65%), and AD (70%) than in controls (43%); DQA1*0301 was significantly more frequent only in
IDDM
(67% vs. 30% controls). The heterozygous state DQA1*0301/*0501 was found in 9% of controls and 35% of
IDDM
(relative risk, 5.6). An
arginine
at position 52 on either DQA1 allele was significantly more frequent in patients with
IDDM
(94%), GD (80%), and AD (89%) compared with controls (66%). HLA DQB1*0201 and DQB1*0302 were more frequent in
IDDM
patients (*0201, 62% vs. 36% in controls, *0302, 59% vs. 19% controls), whereas DQB1*0602 was less frequent in
IDDM
(4%) and GD (18% vs. 31% of controls). In conclusion, endocrine autoimmunity has a common immunogenetic background; susceptibility is conferred by DQA1*0501 as well as an
arginine
at position 52 of DQA1 alleles, and protection against
IDDM
and GD is conferred by DQB1*0602.
...
PMID:Susceptibility and resistance alleles of human leukocyte antigen (HLA) DQA1 and HLA DQB1 are shared in endocrine autoimmune disease. 760 64
1.
Diabetes mellitus type I
was induced in 3-month old male C57 BL/KS-mdb mice (N = 24) by ip injection of streptozotocin (STZ, 45 mg/kg body weight) for 5 days. 2. To determine the possible protective effects of nitric oxide inhibition against hyperglycemia, the STZ-diabetic rats received two doses of NG-nitro-L-
arginine
- methyl ester (L-NAME) (10 mg/kg body weight and 10 mg/mouse) dissolved in PBS for 45 consecutive days. Another group of STZ-treated rats was similarly treated with L-
arginine
(5 mg/mouse). 3. Blood glucose levels were 118 +/- 37 mg/dl after 8 days of L-NAME administration (10 mg/kg body weight, N = 12) and 186 +/- 22 mg/dl (N = 12) after 5 days of L-NAME administration at the 5 mg/mouse dose. Treatment with L-
arginine
(5 mg/mouse, N = 12) caused a significant increase in blood glucose level to 151 +/- 17.5 mg/dl, showing the relevance of nitric oxide formation in this type of diabetes. 4. In STZ-diabetic mice treated with L-NAME (N = 12), diuresis was reduced by approximately 58% compared to STZ animals, whereas in L-
arginine
-treated animals (N = 12) diuresis returned to STZ levels. Urinary protein excretion, which was significantly affected by STZ (123% compared to control) was significantly reduced by 66% after treatment with L-NAME for 45 days, whereas treatment with L-
arginine
caused a return to STZ values. 5. Urinary kallikrein excretion, which was reduced by 80% in STZ mice compared to control, returned to control levels after L-NAME treatment. 6. The present results suggest a relationship between nitric oxide levels and the reduction of diabetic state and improved renal function by L-NAME.
...
PMID:Streptozotocin-induced hyperglycemia is decreased by nitric oxide inhibition. 774 93
Children with
IDDM
have diminished glucagon responses to hypoglycemia. We evaluated possible mechanisms in 60 children and adolescents with
IDDM
(age 15.4 +/- 2.6 years, duration 7.8 +/- 3.5 years [mean +/- SD]) and without diabetic complications. These were: 1) suppression by hyperinsulinism, 2) autonomic neuropathy, 3) a pan-islet cell defect, and 4) a glucotoxic effect. Glucagon and pancreatic polypeptide responses to hypoglycemia (insulin bolus 0.15-0.75 U/kg) were studied after insulin withdrawal and 3 days of intensive insulin therapy. Responses to
arginine
and mixed meal were also studied. The control group consisted of children with non-growth hormone deficient short stature.
IDDM
children had lower glucagon responses to hypoglycemia than controls (p < 0.001), the response to
arginine
did not differ from controls, and was greater than the response to hypoglycemia (p < 0.001). Responses to hypoglycemia after insulin withdrawal and intensive therapy did not differ. Basal pancreatic polypeptide levels were lower in
IDDM
than in controls (p < 0.05) but responses to hypoglycemia did not differ between groups. Thus the diminished glucagon response to hypoglycemia reflects a defect in hypoglycemic recognition or response by the alpha cells.
...
PMID:Abnormal alpha cell hypoglycemic recognition in children with insulin dependent diabetes mellitus (IDDM). 782 Feb 17
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>